spacer
home > epc > spring 2002 > clinical trials and new drug applications in japan
PUBLICATIONS
European Pharmaceutical Contractor

Clinical Trials and New Drug Applications in Japan

The Common Technical Document (CTD) is a major step towards internationally recognised marketing authorisation applications, but its success will be affected by processes at a national level. In Japan, a number of recent clinical, ethical, regulatory and review changes also serve to provide even better access to this important region.

There has been considerable change in the Japanese regulatory framework over the last five years or so, driven by external (ICH) and internal (government) factors. The result is more effective, transparent and manageable approval processes.

With a population of 125 million (1), a recent international agreement on the CTD, and significant inclusion of other ICH steps, Japan represents a sizeable and accessible marketplace for research and marketing - more than ever before. In the mid- to late nineties, in excess of 7,000 ethical, over-the-counter (OTC) and quasi-drug manufacturing licences were held in Japan (1,2). With that in mind, the essential steps to obtain approval for clinical trials and to obtain marketing authorisation are described below.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tony Mitchell, Director of Regulatory Affairs at Origin Pharmaceutical Services Limited

Dr Tony Mitchell is Director of Regulatory Affairs and Strategic Services at Origin Pharmaceutical Services Limited.

He has considerable experience in the international registration of pharmaceutical products. He previously held regulatory positions at Fisons Pharmaceuticals, British Biotech Pharmaceuticals Limited and Pharmakopius, the international contract research organisation.

spacer
Dr Tony Mitchell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder


More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement